Anbio Biotechnology(NNNN) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 11 at 7:46 PM ET (Korea 9/12 08:46)
Full metrics table
| Index | - | P/E | 38.73 | EPS (ttm) | 0.16 | Insider Own | 9.57% | Shs Outstand | 43.9M | Perf Week | -3.94% |
| Market Cap | 0.91B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 39.7M | Perf Month | -35.89% |
| Enterprise Value | 0.90B | PEG | - | EPS next Q | - | Inst Own | 0.16% | Short Float | 0.15% | Perf Quarter | -61.44% |
| Income | 0.01B | P/S | 93.66 | EPS this Y | - | Inst Trans | 1.39% | Short Ratio | 0.52 | Perf Half Y | -71.87% |
| Sales | 0.01B | P/B | 7.86 | EPS next 5Y | - | ROA | 26.08% | Short Interest | 0.06M | Perf YTD | -78.92% |
| Book/sh | 0.81 | P/C | 65.26 | EPS past 3/5Y | -12.86% 23.44% | ROE | 27.01% | 52W High | -87.65% ($51.33) | Perf Year | -85.45% |
| Cash/sh | 0.1 | P/FCF | - | Sales past 3/5Y | -26.67% 16.85% | ROIC | 20.29% | 52W Low | 3.43% ($6.13) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | 138.62 | EPS Y/Y TTM | 170.13% | Gross Margin | 87.06% | Volatility(W/M) | 7.74% 15.3% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | 92.23 | Sales Y/Y TTM | 10.1% | Oper. Margin | 66.47% | ATR (14) | 1 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 344.31 | EPS Q/Q | 321.09% | Profit Margin | 73.75% | RSI (14) | 28.65 | Recom | - |
| Dividend Gr. 3/5Y | - | Current Ratio | 344.31 | Sales Q/Q | 87.39% | SMA20 | -13.55% ($7.33) | Beta | 5.24 | Target Price | - |
| Payout | - | Debt/Eq | 0 | Earnings | - | SMA50 | -30.41% ($9.11) | Rel Volume | 2.4 | Prev Close | $6.51 |
| Employees | 27 | LT Debt/Eq | 0 | EPS/Sales Surpr. | - | SMA200 | -71.27% ($22.07) | Avg Volume(3M) | 0.11M | Price | $6.34 |
| IPO | 2025/2/19 | Option/Short | No/Yes | Trades | 1539 | Volume | 268,641 | Change | -2.61% |
Company
NNNN is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
🧪 A Germany-based diagnostics company that supplies in vitro diagnostic (IVD) products. It develops and supplies rapid diagnostic kits as well as immunoassay and molecular diagnostic solutions, and sells diagnostic products in global markets including Europe, Asia, and the Americas. It is a newly listed company in the in vitro diagnostics field.
Over the past 1 year, on the lower side
88% below its 1-year high.
NNNN makes money exceptionally well
66.47% of revenue is kept as operating profit.
Tap to view numbers
But it is not cheap
Trading at 38.7 times earnings.
Tap to view numbers
Holding long would have lost money
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 0.2%.
Tap to view numbers
It ranks #4 in the industry
Based on market cap of $912M.
NNNN $912M PER 38.7
ISRG $131B PER 42.4
BDX $48B PER 53.6
MDLN $43B PER 38.1
FAQ
What kind of company is NNNN?
NNNN belongs to the Healthcare sector and operates in the Medical Instruments & Supplies industry.
What is the market cap of NNNN?
The market cap of NNNN is approximately $912M, ranking 2,713 within its sector.
What is the P/E ratio of NNNN?
NNNN has a P/E ratio of approximately 38.7x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for NNNN?
NNNN has recorded a 52-week high of $51.33 and a low of $6.13.
